Open Access

[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway

  • Authors:
    • Junpeng Ji
    • Tianyu Shen
    • Yang Li
    • Yixi Liu
    • Zhiqun Shang
    • Yuanjie Niu
  • View Affiliations

  • Published online on: July 17, 2023     https://doi.org/10.3892/or.2023.8602
  • Article Number: 165
  • Copyright : © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

September-2023
Volume 50 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ji J, Shen T, Li Y, Liu Y, Shang Z and Niu Y: [Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway. Oncol Rep 50: 165, 2023
APA
Ji, J., Shen, T., Li, Y., Liu, Y., Shang, Z., & Niu, Y. (2023). [Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway. Oncology Reports, 50, 165. https://doi.org/10.3892/or.2023.8602
MLA
Ji, J., Shen, T., Li, Y., Liu, Y., Shang, Z., Niu, Y."[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway". Oncology Reports 50.3 (2023): 165.
Chicago
Ji, J., Shen, T., Li, Y., Liu, Y., Shang, Z., Niu, Y."[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway". Oncology Reports 50, no. 3 (2023): 165. https://doi.org/10.3892/or.2023.8602